Pilot Study of 18F-FLT PET

University of Wisconsin, Madison15 enrolled

Overview

Fractionated radiotherapy induces an observable change in the proliferative activity as assessed by pre-treatment and early-treatment 18F-FLT PET imaging. This study is designed to investigate 18F-FLT as a PET imaging agent for predicting treatment effectiveness in several tumors and will serve as a pilot study to a planned PO1 submission

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

CNS Brain Metastasis Head and Neck Cancer Lung Cancer Prostate Cancer Esophageal Cancer

Interventions

Imaging with 18F-FLT PETPROCEDURE

Imaging with 18F-FLT PET

Imaging with 18F-FLT PETPROCEDURE

Imaging with 18F-FLT PET

Imaging with 18F-FLT PETPROCEDURE

Imaging with 18F-FLT PET

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Able to tolerate a PET/CT scan * Age of 18 or older * signed informed consent * being considered for radiotherapy for treatment of CNS mets, Head and neck cancer, lung cancer, prostate cancer or esophageal cancer Exclusion Criteria: * Prior XRT to site being studied * severe claustrophobia or inability to tolerate PET/CT * unable to provide written consent * pregnant or breastfeeding women

Locations (1)

University of Wisconsin Hospital and clinis

Madison, Wisconsin, United States

Outcomes

Primary Outcomes

To test whether the cellular response to fractionated radiotherapy leads to observable global change in the uptake of 18F-FLT as assessed by PET imaging

Time frame: end of study

Secondary Outcomes

To assess the technical and logistic feasibility of 18F-FLT scans in a population of cancer patients

Time frame: end of study

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.